Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
Launched by TURKU UNIVERSITY HOSPITAL · Nov 23, 2018
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Vascular adhesion protein 1 (VAP-1) is an inflammation inducible endothelial cell molecule mediating leukocyte trafficking from blood into the sites of inflammation. Although VAP-1 plays important role in early phases of inflammation, its luminal expression on the endothelium will remain constant if the inflammation continues, which suggest VAP-1 as a promising target for molecular imaging of inflammation. We have previously shown that sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) is a VAP-1 ligand, and the gallium-68 labeled 1,4,7,10-tetraazacyclododecane-N,N´,N´´,N´´´-tetraa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy 18-70 year-old men
- • Male or female 18-70 year-old patients with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis
- Exclusion Criteria:
- • In healthy: ongoing infection/inflammation proven by blood or other tests
- • In patients with rheumatoid arthritis: no treatment with disease-modifying anti-rheumatic drugs or biologic agents, and no corticosteroids for 2 weeks prior the study
- • In patients with vasculitis: no immunosuppressives, and glucocorticoid less than 60 mg for 2 weeks or NSAIDs for 1 day prior the study
- • In patients with pulmonary sarcoidosis: no corticosteroids for 1 week or NSAIDs for day prior the study
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Anne Roivainen, Professor
Principal Investigator
Turku University Hospital, Turku PET Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials